Commercial

Pfizer deals extend patent life for a top-selling rare disease drug

BioPharma Dive

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.

Rare Disease

Read full story

pharminent April 28, 2026 (Last updated: April 29, 2026)

BioPharma Dive

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.

Rare Disease

Read full story

Related Stories

Pfizer settles with generic drugmakers to protect blockbuster drug until 2031

Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’

Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remedies

You May Have Missed

Pfizer settles with generic drugmakers to protect blockbuster drug until 2031

AZ, Amgen will pilot FDA’s real-time clinical trial plan

AstraZeneca faces uphill battle at upcoming adcomm in face of FDA questions

Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’